Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors.

Solid tumors produce both stimulators and inhibitors of angiogenesis. The suppression of metastases by some primary tumors has been attributed to the longer circulatory half-lives of the inhibitors. We propose that intrinsic differences in the physicochemical properties of these regulators may also explain focal suppression of angiogenesis within the primary tumor. We present a mathematical framework that describes production, diffusion, and degradation of these factors in tumor and host tissue and their effect on angiogenesis at local and distal sites. Results show focal suppression of angiogenesis, provide an explanation for tumor dormancy and focal necrosis, and predict a suppressive influence of primary tumors on angiogenesis at metastatic sites. They suggest generally that diffusible factors produced by tumors can stimulate responses in adjacent host tissue, preparing it for further tumor invasion. This study presents a new paradigm for the development of tumor necrosis and offers new insight into angiogenesis regulation and therapy. The framework established for modeling the competing effects of diffusible stimulators and inhibitors can be applied more generally to growth factors/inhibitors and other opposing factors produced in the tumor environment.

[1]  I. Tannock,et al.  THE RELATION BETWEEN CELL PROLIFERATION AND THE VASCULAR SYSTEM IN A TRANSPLANTED MOUSE MAMMARY TUMOUR , 2007 .

[2]  E. Gillette,et al.  Morphometric analyses of the microvasculature of tumors during growth and after x‐irradiation , 1974, Cancer.

[3]  P. Vaupel Hypoxia in neoplastic tissue. , 1977, Microvascular research.

[4]  M Intaglietta,et al.  Tissue perfusion inhomogeneity during early tumor growth in rats. , 1979, Journal of the National Cancer Institute.

[5]  R. Sutherland,et al.  Oxygen diffusion distance and development of necrosis in multicell spheroids. , 1979, Radiation research.

[6]  L. Woolner,et al.  Occult papillary carcinoma of the thyroid. , 1980, Archives of surgery.

[7]  C. Prowse,et al.  A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. , 1983, Thrombosis research.

[8]  R K Jain,et al.  Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.

[9]  Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. , 1985, Thrombosis research.

[10]  K. Franssila,et al.  Occult papillary carcinoma of the thyroid. A “normal” finding in finland. A systematic autopsy study , 1985, Cancer.

[11]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[12]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[13]  R K Jain,et al.  Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Wagner,et al.  Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half‐life , 1989, Journal of cellular physiology.

[15]  Peter J. Polverini,et al.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.

[16]  R T Prehn,et al.  The inhibition of tumor growth by tumor mass. , 1991, Cancer research.

[17]  N. Mayr,et al.  Morphometric studies in intraductal breast carcinoma using computerized image analysis , 1991, Cancer.

[18]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[19]  H. Lyng,et al.  Blood flow in six human melanoma xenograft lines with different growth characteristics. , 1992, Cancer research.

[20]  R. Prehn Two competing influences that may explain concomitant tumor resistance. , 1993, Cancer research.

[21]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Delmas,et al.  Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. , 1993, Cancer research.

[23]  A. Uchida,et al.  Serum concentrations of basic fibroblast growth factor in breast cancer. , 1994, Clinical chemistry.

[24]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[25]  P. Hahnfeldt,et al.  Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. , 1994, Cancer research.

[26]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[27]  R. Demicheli,et al.  Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[28]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[29]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[30]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[31]  S. Soker,et al.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.

[32]  S. Koscielny,et al.  Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[33]  K Groebe,et al.  On the relation between size of necrosis and diameter of tumor spheroids. , 1996, International journal of radiation oncology, biology, physics.

[34]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[35]  M. Toi,et al.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[37]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[38]  R K Jain,et al.  Direct in vivo measurement of targeted binding in a human tumor xenograft. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Paolo A. Netti,et al.  Solid stress inhibits the growth of multicellular tumor spheroids , 1997, Nature Biotechnology.

[40]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[41]  S. Szabó,et al.  The diagnostic and prognostic value of tumor angiogenesis. , 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[42]  R. Jain,et al.  Delivery of Molecular and Cellular Medicine to Solid Tumors , 1997, Advanced drug delivery reviews.

[43]  R K Jain,et al.  Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. , 1998, Cancer research.

[44]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[45]  S. Ménard,et al.  Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  W. Deen Analysis Of Transport Phenomena , 1998 .

[47]  R. Timpl,et al.  Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin , 1998, The EMBO journal.

[48]  J. Folkman,et al.  Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. , 1998, Archives of dermatology.

[49]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[50]  N. Nelson Angiogenesis research is on fast forward. , 1999, Journal of the National Cancer Institute.

[51]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[52]  R K Jain,et al.  Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.

[53]  R. Jain Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[54]  Ridgway Pf Tumours : wounds that do not heal. , 2002 .